Chugai Secures Licensing Deal with Roche for Hypertension Drug Zilebesiran in Japan.

April 24th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Cerevel Therapeutics Reveals Encouraging Initial Outcomes from Phase 3 Supplementary Study of Tavapadon in Parkinson’s Disease Patients.

The storage method for radioactive drugs needs to follow specific safety and protection standards to ensure the safety and effectiveness of radioactive substances.

D2M Biotherapeutics has initiated a Phase 1 trial by administering the first dose of DM919, an innovative MICA/B antibody, aimed at treating individuals with advanced solid tumors.

On April 22, 2024, ImmunityBio's Anktiva (N-803) plus BCG got FDA approval for BCG-unresponsive NMIBC with CIS, with/without papillary tumors.

Pathios Therapeutics Secures $25M in Initial Series B Funding Round to Propel Unique Immunotherapy Strategy into Clinical Trials.

Commonly used radioactive isotopes include 125I and 131I, which can undergo iodination reactions with the tyrosine residues in the antibody.

GV20 Therapeutics Reveals Partnership for Clinical Study to Test GV20-0251, an Innovative Antibody Targeting New Immune Checkpoint IGSF8, Together with KEYTRUDA® (pembrolizumab).

The Synapse Database for Translational Medicine is now live, come and experience it!

Results from the Phase 3 SELECT-GCA trial indicate that Upadacitinib (RINVOQ®) offers promising outcomes for individuals with Giant Cell Arteritis.

In the design process of shRNA (short hairpin RNA), the fragment length is an important consideration factor, as it can affect the efficiency and specificity of RNA interference (RNAi).